| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000247 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS46000268 | BKPyv | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003768 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30013351 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008906 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30003769 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016333 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30016334 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30008907 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30000694 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C1 |
|---|---|
| DrugBank ID | DB00635 |
| Drug Name | Prednisone |
| Target ID | BE0000794 |
| UniProt ID | P04150 |
| Regulation Type | agonist |
| PubMed IDs | 17121036; 16597193; 17504182; 17062674; 16707595; 11752352; 15634032 |
| Citations | Liu BG, Li ZY, Du M: [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Oct;26(10):881-4.@@Friel PN, Alexander T, Wright JV: Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.@@Diez JJ, Iglesias P: Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem. 2007 May;7(5):467-80.@@Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K: Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7.@@Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15;12(10):3003-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. |
| Groups | Approved; Vet_approved |
| Direct Classification | 21-hydroxysteroids |
| SMILES | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
| Pathways | Prednisone Metabolism Pathway; Prednisone Action Pathway |
| PharmGKB | PA451100 |
| ChEMBL | CHEMBL635 |
